Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702132 | 0.85 | ALDH1A1 (0.52) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL1783365 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL1783245 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL8213846 | 0.79 | NPC1 (0.66) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL1781479 | 0.79 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL8355892 | 0.79 | GNG2 (0.65) | — | |
| SCHEMBL8358129 | 0.79 | GNG2 (0.65) | — | |
| SCHEMBL30702196 | 0.78 | ALDH1A1 (0.57) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL18328435 | 0.77 | LMNA (0.57) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 | |
| SCHEMBL26343040 | 0.77 | LMNA (0.57) | SMN1; SMN2LMNARAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | SMN1; SMN2 166/4885LMNA 1017/4885RAB9A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.